Current management for late normal tissue injury... (2007 study) Skip to main content
RCT Seminars in radiation oncology 2007

Current management for late normal tissue injury: radiation-induced fibrosis and necrosis.

Delanian S, Lefaix JL, Seminars in radiation oncology, 2007

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

The authors wrote a review of the treatments used for radiation-induced fibrosis and radionecrosis, which are long-term tissue damage after radiation therapy.

What They Found

This review article summarizes current management options for radiation-induced fibrosis (RIF) and radionecrosis (RN), late complications that are usually considered irreversible. For moderate established RIF, the abstract lists anti-inflammatory treatment with corticosteroids or interferon gamma, vascular therapy with pentoxifylline or hyperbaric oxygen (HBO), and antioxidant treatment, with a pentoxifylline-vitamin E combination described as the most successful antioxidant option. For RN, the abstract lists corticosteroids and possibly clodronate, vascular therapy with HBO and pentoxifylline, and combinations of pentoxifylline with vitamin E, with or without clodronate. The abstract reports no numbers, and it notes that results of clinical studies are hard to compare because of differences in severity, assessment methods, treatment duration and trial quality.

What This Means for Canadian Patients

For people with late radiation injury, the abstract names HBO as one of the vascular therapy options for both fibrosis and necrosis, alongside drug treatments. It does not give HBO pressures, session counts or results, and it does not say HBO works better than the other options. The authors say controlled randomized trials are now needed to identify the best treatment at each step, so treatment choices are best discussed with a treating physician.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

This is a narrative review rather than a trial, it reports no patient numbers or outcome data, and the authors state that the studies it draws on are difficult to compare and that randomized trials are still needed.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type RCT
Category Radiation Injury
Source Pubmed
PubMed ID 17395040
Year Published 2007
Journal Seminars in radiation oncology
MeSH Terms Adrenal Cortex Hormones; Antioxidants; Atrophy; Dose-Response Relationship, Radiation; Fibrosis; Humans; Hyperbaric Oxygenation; Interferon-gamma; Necrosis; Pentoxifylline; Radiation Injuries; Radiation-Protective Agents; Radiotherapy

Cite This Study

Share

This study relates to Delayed Radiation Injury. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Radiation Injury

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: April 1, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology